查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362982

iPS 细胞（诱导性多功能干细胞）市场规模、份额和趋势分析报告：按衍生细胞类型、应用、最终用途、地区和细分市场预测，2023-2030 年

Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development, Toxicology Research), End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

iPS细胞（诱导性多功能干细胞）市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球iPS细胞市场规模将达到30.9亿美元，2023年至2030年年复合成长率为10.61%。

iPS 细胞 (iPSC) 市场正在迅速扩大。其使用的主要原因是iPS细胞可以生成人体必需的所有细胞和组织，以对抗和对抗白血病、脊髓损伤、心血管疾病和糖尿病等疾病。

推动市场扩张的其他因素包括研究支出的增加、基因组学计划的增加以及基因组工程在个体化治疗中的应用迅速增加。因此，iPSC 的采用正在加速，从而导致市场收益成长。例如，2020 年 10 月，Axxam SpA 和 FUJIFILM Cellular Dynamics, Inc. 宣布建立策略伙伴关係，以推进药物研发过程。透过使用能够实现标靶评估、高通量筛选 (HTS) 和高内涵筛选的尖端药物研发技术，这项合作伙伴关係将为药物研发研究人员和科学家提供基于 hiPSC 检测的整合平台。去做。

近年来，医疗开发和研究的投资大幅增加，预计这一趋势将对预测期内 iPS 细胞的需求产生重大影响。人类iPSC细胞株在精准医疗中应用范围的扩大以及对干细胞治疗应用的日益重视预计将成为推动iPS细胞市场扩张的重要因素。例如，根据两家公司的联合声明，2021 年 3 月，Sana Biotechnology 获得批准使用FUJIFILM Cellular Dynamics 的 iPSC 平台来创建商业性化的细胞疗法。细胞疗法可以改善、修改或替代人类生物学，包括细胞、组织和器官。

COVID-19 大流行期间研究活动的活性化也促进了 iPSC 的研究。此外，科学家们不断努力发现新治疗方法和控制 SARS CoV-2 感染的治疗方法，这增加了对 iPSC 作为研究工具的需求。此外，iPS 细胞可用于研究人类病毒感染的病理学，因为它们可以产生生理上等效的类器官和器官模型。因此，它支撑着产业的发展。

此外，随着专注于与 iPS 细胞相关的各种科学活动的行业的发展，政府和商业部门正在增加资金，公众对干细胞的认识也透过各种组织不断提高。然而，细胞重编程成本高、伦理问题、流程耗时等挑战在某种程度上阻碍了iPS细胞产业的发展。此外，低效率、潜在肿瘤风险和糟糕的程式设计也是限制 iPSC 市场扩张的问题。

iPS 细胞市场报告亮点

  • 从衍生细胞类型来看，纤维母细胞片段占比最大，2022年为30.48%。医学专业人士越来越偏好将成纤维母细胞作为皮肤问题的潜在治疗方法，这正在推动该领域的发展。
  • 按应用来看，药物研发领域占比最大，2022年为49.09%。慢性病的流行、久坐的生活方式等正在增加对个体化治疗的需求，而製药和生物技术公司对借助 iPS 细胞开发药物的兴趣日益浓厚，正在推动该行业的成长。
  • 按最终用途划分，製药和生物技术公司占最大份额，2022年为59.77%。该细分市场预计将主导市场，因为它使用 iPS 细胞製造和开发针对各种疾病的各种干细胞产品和技术。
  • 2022年，北美将占据42.36%的较大份额。这主要是由于创新系统和技术在药物研究、毒性测试和疾病建模方面的使用越来越多，而该地区对干细胞疗法的日益接受度也推动了市场的发展，这是主要因素。

目录

第1章调查方法和范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场体系展望
  • 市场趋势及展望
  • 市场动态
  • 市场抑制因素分析
  • 营商环境分析

第4章衍生细胞类型的业务分析

  • 全球 iPS 细胞市场：衍生细胞类型的变异分析
  • 肝细胞
  • 纤维母细胞
  • 角质形成细胞
  • 羊膜细胞
  • 其他的

第5章商业分析的应用

  • 全球 iPS 细胞市场：应用变化分析
  • 药物开发
  • 组织工程与再生医学
  • 毒理学研究
  • 疾病建模

第6章最终用户业务分析

  • 全球 iPS 细胞市场：最终用户波动分析
  • 学术/研究机构
  • 製药和生物技术公司
  • 其他的

第7章区域业务分析

  • 全球 iPS 细胞市场占有率（按地区划分，2022 年和 2030 年）
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章竞争形势

  • 公司分类
  • 策略规划
  • 2022 年公司市场占有率分析
  • 公司简介/名单
    • STEMCELL Technologies Inc.
    • Cellular Engineering Technologies Inc.
    • REPROCELL Inc.
    • Takara Bio, Inc.
    • Axol Bioscience Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Corporation（FUJIFILM Cellular Dynamics, Inc.）
    • Cynata Therapeutics Limited
    • Evotec SE
    • Astellas Pharma Inc.
Product Code: GVR-4-68040-116-1

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.09 billion by 2030 and is expected to expand at a CAGR of 10.61% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report highlights

  • By derived cell type, the fibroblasts segment accounted for the largest share of 30.48% in 2022. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
  • By application, the drug developmentsegment accounted for the largest share of 49.09% in 2022. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
  • By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.77% in 2022. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
  • North America held the larger share of 42.36% in 2022. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Europe Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Increase in research and development activities in stem cells therapies
    • 3.3.2. Surge in adoption of personalized medicine
  • 3.4. Market Restraint Analysis
    • 3.4.1. Lack of awareness regarding stem cell therapies
    • 3.4.2. High cost of treatment
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Derived Cell Type Business Analysis

  • 4.1. Global induced pluripotent stem cells market: Derived Cell Type Movement Analysis
  • 4.2. Hepatocytes
    • 4.2.1. Hepatocytes Market, 2018 - 2030 (USD Million)
  • 4.3. Fibroblasts
    • 4.3.1. Fibroblasts Market, 2018 - 2030 (USD Million)
  • 4.4. Keratinocytes
    • 4.4.1. Keratinocytes Market, 2018 - 2030 (USD Million)
  • 4.5. Amniotic Cells
    • 4.5.1. Amniotic Cells Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Global induced pluripotent stem cells market: Application Movement Analysis
  • 5.2. Drug Development
    • 5.2.1. Drug Development Market, 2018 - 2030 (USD Million)
  • 5.3. Tissue Engineering & Regenerative Medicine
    • 5.3.1. Tissue Engineering & Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 5.3.2. Neurology
      • 5.3.2.1. Neurology Market, 2018 - 2030 (USD Million)
    • 5.3.3. Orthopedics
      • 5.3.3.1. Orthopedics Market, 2018 - 2030 (USD Million)
    • 5.3.4. Oncology
      • 5.3.4.1. Oncology Market, 2018 - 2030 (USD Million)
    • 5.3.5. Cardiovascular and Myocardial Infraction
      • 5.3.5.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Million)
    • 5.3.6. Diabetes
      • 5.3.6.1. Diabetes Market, 2018 - 2030 (USD Million)
    • 5.3.7. Others
      • 5.3.7.1. Others Market, 2018 - 2030 (USD Million)
  • 5.4. Toxicology Research
    • 5.4.1. Toxicology Research Market, 2018 - 2030 (USD Million)
  • 5.5. Disease Modeling
    • 5.5.1. Disease Modeling Market, 2018 - 2030 (USD Million)

Chapter 6. End-User Business Analysis

  • 6.1. Global induced pluripotent stem cells market: End-User Movement Analysis
  • 6.2. Academic & Research Institutes
    • 6.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 6.3. Pharmaceutical & Biotechnology Companies
    • 6.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Global Induced Pluripotent Stem Cells Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Target Disease Prevalence
      • 7.2.2.5. U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Target Disease Prevalence
      • 7.2.3.5. Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Induced Pluripotent Stem Cells Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Target Disease Prevalence
      • 7.3.2.5. Germany induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Target Disease Prevalence
      • 7.3.3.5. UK induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Target Disease Prevalence
      • 7.3.4.5. France induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Target Disease Prevalence
      • 7.3.5.5. Italy induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Target Disease Prevalence
      • 7.3.6.5. Spain induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Target Disease Prevalence
      • 7.3.7.5. Denmark induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Target Disease Prevalence
      • 7.3.8.5. Sweden induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Target Disease Prevalence
      • 7.3.9.5. Norway induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Target Disease Prevalence
      • 7.4.2.5. Japan induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Target Disease Prevalence
      • 7.4.3.5. China induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Target Disease Prevalence
      • 7.4.4.5. India induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Target Disease Prevalence
      • 7.4.5.5. South Korea induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Target Disease Prevalence
      • 7.4.6.5. Australia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Target Disease Prevalence
      • 7.4.7.5. Thailand induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Target Disease Prevalence
      • 7.5.2.5. Brazil induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Target Disease Prevalence
      • 7.5.3.5. Mexico induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Target Disease Prevalence
      • 7.5.4.5. Argentina induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Target Disease Prevalence
      • 7.6.2.5. South Africa induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Target Disease Prevalence
      • 7.6.3.5. Saudi Arabia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Target Disease Prevalence
      • 7.6.4.5. UAE induced pluripotent stem cells market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Target Disease Prevalence
      • 7.6.5.5. Kuwait induced pluripotent stem cells market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2022
  • 8.4. Company Profiles/Listing
    • 8.4.1. STEMCELL Technologies Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Cellular Engineering Technologies Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. REPROCELL Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Takara Bio, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Axol Bioscience Ltd.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Fate Therapeutics, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. FUJIFILM Corporation (FUJIFILM Cellular Dynamics, Inc.)
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Cynata Therapeutics Limited
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Evotec SE
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Astellas Pharma Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 4 Global Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 5 Global Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 6 North America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 7 North America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 8 North America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 9 North America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 10 U.S. Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 16 Europe Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 20 UK Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 21 UK Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 22 UK Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 25 Germany Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 26 France Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 27 France Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 28 France Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 29 Italy Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 31 Italy Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 32 Spain Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 34 Spain Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 35 Denmark Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 37 Denmark Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 38 Sweden Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 40 Sweden Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 41 Norway Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 43 Norway Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 48 China Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 49 China Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 50 China Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 51 Japan Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 53 Japan Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 54 India Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 55 India Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 56 India Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 57 South Korea Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 59 South Korea Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 60 Australia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 62 Australia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 63 Thailand Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 65 Thailand Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 66 Latin America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 68 Latin America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 70 Brazil Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 72 Brazil Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 73 Mexico Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 75 Mexico Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Induced Pluripotent Stem Cells Market by End-User, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
  • Table 83 South Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 85 South Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 91 UAE Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Induced Pluripotent Stem Cells Market By End-Use, 2018 - 2030 (USD Million)
  • Table 95 Participant's Overview
  • Table 96 Financial Performance
  • Table 97 Key Companies Undergoing Expansions
  • Table 98 Key Companies Undergoing Acquisitions
  • Table 99 Key Companies Undergoing Collaborations
  • Table 100 Key Companies Launching New Products/Services
  • Table 101 Key Companies Undergoing Partnerships
  • Table 102 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global induced pluripotent stem cells market: Derived cell type outlook and key takeaways
  • Fig. 16 Global induced pluripotent stem cells market: Derived cell type movement analysis
  • Fig. 17 Global hepatocytes market, 2018 - 2030 (USD Million)
  • Fig. 18 Global fibroblasts market, 2018 - 2030 (USD Million)
  • Fig. 19 Global keratinocytes market, 2018 - 2030 (USD Million)
  • Fig. 20 Global amniotic cells market, 2018 - 2030 (USD Million)
  • Fig. 21 Global others market, 2018 - 2030 (USD Million)
  • Fig. 22 Global induced pluripotent stem cells market: Application outlook and key takeaways
  • Fig. 23 Global induced pluripotent stem cells market: Application movement analysis
  • Fig. 24 Global drug development market, 2018 - 2030 (USD Million)
  • Fig. 25 Global tissue engineering & regenerative medicine market, 2018 - 2030 (USD Million)
  • Fig. 26 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 27 Global orthopedics market, 2018 - 2030 (USD Million)
  • Fig. 28 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 29 Global cardiovascular and myocardial infraction market, 2018 - 2030 (USD Million)
  • Fig. 30 Global diabetes market, 2018 - 2030 (USD Million)
  • Fig. 31 Global others market, 2018 - 2030 (USD Million)
  • Fig. 32 Global toxicology research market, 2018 - 2030 (USD Million)
  • Fig. 33 Global disease modeling market, 2018 - 2030 (USD Million)
  • Fig. 34 Global induced pluripotent stem cells market: End-use outlook and key takeaways
  • Fig. 35 Global induced pluripotent stem cells market: End-use movement analysis
  • Fig. 36 Global academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 37 Global pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
  • Fig. 38 Global induced pluripotent stem cells market: Regional outlook and key takeaways
  • Fig. 39 North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
  • Fig. 44 Europe induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Germany key country dynamics
  • Fig. 46 Germany induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 France key country dynamics
  • Fig. 48 France induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Asia-Pacific induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 India key country dynamics
  • Fig. 65 India induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea key country dynamics
  • Fig. 67 South Korea induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Australia key country dynamics
  • Fig. 71 Australia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 MEA induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Market participant categorization
  • Fig. 91 induced pluripotent stem cells market share analysis, 2022
  • Fig. 92 Strategy framework